Rgenix is a privately-held clinical-stage biopharmaceutical company developing first-in-class drugs that target key pathways in cancer progression.

310 E 67th St, Suite 1-12‎ New York, NY
(646) 856-9261
info@inspirna.com

Celia Andreu, PhD

Principal Scientist

Celia leads Inspirna’s target discovery efforts using the RNA-DRIVErTM platform.  She is also responsible for translational sciences and biomarker discovery and the validation of Inspirna’s drug candidates.  Celia received her undergraduate degree in Pharmacology and her Ph.D. in Neurobiology from University of Valencia in Spain. Prior to joining Inspirna, she was a postdoctoral fellow at Memorial Sloan Kettering-Cancer where she studied the role of microRNAs in the proliferation of adult neural stem cells using mouse models.  She has led numerous research projects that have been published in high-profile journals including Nature, Nature Neuroscience and Cell. Celia was an EMBO and a NYSTEM fellow recipient and was awarded the MSKCC Postdoctoral Research Award.